Suspected non-AD pathology in mild cognitive impairment
(2015) In Neurobiology of Aging 36(12). p.3152-3162- Abstract
We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had... (More)
We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.
(Less)
- author
- Wisse, Laura E M LU ; Butala, Nirali ; Das, Sandhitsu R ; Davatzikos, Christos ; Dickerson, Bradford C ; Vaishnavi, Sanjeev N ; Yushkevich, Paul A and Wolk, David A
- author collaboration
- publishing date
- 2015-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Aged, Aged, 80 and over, Alzheimer Disease/pathology, Amyloid beta-Peptides/metabolism, Cognition, Cognitive Dysfunction/metabolism, Female, Hippocampus/metabolism, Humans, Male, Memory, Middle Aged, Nerve Degeneration, Neuroimaging, Peptide Fragments/metabolism
- in
- Neurobiology of Aging
- volume
- 36
- issue
- 12
- pages
- 11 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:84946562079
- pmid:26422359
- ISSN
- 1558-1497
- DOI
- 10.1016/j.neurobiolaging.2015.08.029
- language
- English
- LU publication?
- no
- additional info
- Copyright © 2015 Elsevier Inc. All rights reserved.
- id
- b70d63c8-1cef-4e85-8784-5570b76fda00
- date added to LUP
- 2024-02-28 14:59:32
- date last changed
- 2024-06-09 06:21:14
@article{b70d63c8-1cef-4e85-8784-5570b76fda00, abstract = {{<p>We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.</p>}}, author = {{Wisse, Laura E M and Butala, Nirali and Das, Sandhitsu R and Davatzikos, Christos and Dickerson, Bradford C and Vaishnavi, Sanjeev N and Yushkevich, Paul A and Wolk, David A}}, issn = {{1558-1497}}, keywords = {{Aged; Aged, 80 and over; Alzheimer Disease/pathology; Amyloid beta-Peptides/metabolism; Cognition; Cognitive Dysfunction/metabolism; Female; Hippocampus/metabolism; Humans; Male; Memory; Middle Aged; Nerve Degeneration; Neuroimaging; Peptide Fragments/metabolism}}, language = {{eng}}, number = {{12}}, pages = {{3152--3162}}, publisher = {{Elsevier}}, series = {{Neurobiology of Aging}}, title = {{Suspected non-AD pathology in mild cognitive impairment}}, url = {{http://dx.doi.org/10.1016/j.neurobiolaging.2015.08.029}}, doi = {{10.1016/j.neurobiolaging.2015.08.029}}, volume = {{36}}, year = {{2015}}, }